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Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan, is elevated in the brain of patients with
psychotic disorders. Therefore, lowering brain KYNA levels might be a novel approach in the treatment of
psychotic disorders. The present in vivo electrophysiological study aimed to investigate the effect of an
inhibitor of kynurenine aminotransferase (KAT) II, the primary enzyme for KYNA synthesis, on dopamine
(DA) neurons in the ventral tegmental area (VTA). Acute administration of the KAT II inhibitor PF-
04859989 (5 or 10 mg/kg) was associated with a short-onset, time-dependent decrease in ﬁring rate
and burst activity of DA neurons, both parameters reaching a 50% reduction within 45 min. Furthermore,
PF-04859989 reduced the number of spontaneously active DA cells as measured 4e6 after administra-
tion. Pretreatment with D-cycloserine (30 mg/kg) or CGP-52432 (10 mg/kg) prevented the inhibitory
action of PF-04859989 (5 mg/kg) on ﬁring rate and burst ﬁring activity. In contrast, pretreatment with
methyllycaconitine (MLA, 4 mg/kg) did not change the response, whereas picrotoxin (4.5 mg/kg) partially
prevented the inhibitory effects of PF-04859989 (5 mg/kg, i.v.). Our results show that a speciﬁc inhibition
of KAT II is associated with a marked reduction in VTA DA ﬁring activity. This effect appears to be
speciﬁcally executed by NMDA-receptors and mediated indirectly via a GABA(B)-receptor-induced
disinhibition of DA neurons. Our ﬁndings are in line with the view that endogenous KYNA, by modu-
lation of the NMDA-receptor, exerts important physiological roles in the brain.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
During the past decade tryptophan metabolism along the
kynurenine pathway has attracted increasing interest with regard
to the pathophysiology of a large variety of psychiatric and
neurological diseases (Erhardt et al., 2009; Schwarcz et al., 2012).
This pathway, mainly located in the astrocytes and microglia, ap-
pears strongly inﬂuenced by the immune system where the initial
and rate-limiting enzymes indoleamine 2,3-dioxygenase (IDO) and
tryptophan-2,3-dioxygenase (TDO) can be induced as a result of
immune activation (Guillemin et al., 2001; see Schwarcz et al.,
2012; Kozak et al., 2014). Notably, this major tryptophan degrad-
ing metabolism give rise to neuroactive compounds, such as
kynurenic acid (KYNA) and quinolinic acid, the former blocking the.
r Ltd. This is an open access articlglycine site of the N-methyl-D-aspartate (NMDA) receptor as well as
the a7* nicotinic receptor, the latter stimulating the NMDA receptor
(see Schwarcz et al., 2012; Stone et al., 2013).
For long KYNA has been implicated in schizophrenia and a
central elevation of the compound is one of the most consistently
found biochemical aberrations of the disease (Erhardt et al., 2001;
Nilsson et al., 2005; Linderholm et al., 2012; Schwarcz et al.,
2001; Sathysuikumar et al., 2011). In addition, cerebrospinal ﬂuid
(CSF) KYNA is also elevated in euthymic bipolar patients with a
history of psychosis (Olsson et al., 2010, 2012). An involvement of
KYNA in the pathophysiology of psychotic disorders is further
supported by experimental studies showing that elevated levels of
KYNA disrupt prepulse inhibition (PPI) in rats (Erhardt et al., 2004),
which is considered as an analogue behavioral model of disrupted
sensorimotor gating present in patients with schizophrenia (Geyer
et al., 2001). In addition, increased brain levels of KYNA impair
spatial working memory, attentional processing, contextual
learning, social interaction and reward circuitry in rats (Chess ande under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
K.R. Linderholm et al. / Neuropharmacology 102 (2016) 42e47 43Bucci, 2006; Chess et al., 2007, 2009; Trecartin and Bucci, 2011;
Alexander et al., 2012; DeAngeli et al., 2015). Importantly, it has
recently been reported that CSF KYNA is associated with cognitive
impairment seen in patients with bipolar disorder (Sellgren et al.,
2015). Electrophysiological ﬁndings show that brain KYNA has an
important role in the regulation of neuronal activity of midbrain
dopamine (DA) neurons. Whereas elevated levels of brain KYNA are
associated with increased ﬁring rate and burst ﬁring activity of
these neurons, lowered levels diversely lead to a reduction in ﬁring
activity (Erhardt et al., 2001, 2003; Erhardt and Engberg, 2002;
Schwieler and Erhardt, 2003; Nilsson et al., 2006; Schwieler et al.,
2004, 2006, 2008; Linderholm et al., 2007; Olsson et al., 2009).
Altogether, these data imply a reduction in brain KYNA levels as a
novel therapeutic approach for psychotic and cognitive disorders.
Inhibition of kynurenine aminotransferases (KATs), catalyzing the
ﬁnal step in the synthesis of KYNA, would provide a viable option in
this regard. Four KATs have been characterized so far, i.e. KAT I and
KAT II, both preferentially localized in glial cells (Guidetti et al.,
1997), KAT III (Yu et al., 2006) and mitochondrial aspartate
aminotransferase (Guidetti et al., 2007). Under physiological con-
ditions KAT II appears to account for ~75% of the production of
KYNA in the mammalian brain (Guidetti et al., 1997) and speciﬁc
inhibition of this enzyme should signiﬁcantly affect brain KYNA
levels (Rossi et al., 2008). Previous studies have shown that mice
with a targeted deletion of KAT II exhibit decreased brain KYNA
levels that are associated with increased performance in cognitive
paradigms (Potter et al., 2010). Further, a recent study show that
administration of PF-04859989, a selective KAT II inhibitor, pre-
vents amphetamine- or ketamine-induced disruption of sensory
processing and improve cognitive function in rodents and
nonhuman primates (Kozak et al., 2014).
In the present in vivo electrophysiological study, we investigate
the effects of PF-04859989 on the ﬁring activity of DA neurons in
the ventral tegmental area (VTA). Furthermore, a series of electro-
physiological experiments was conducted to study the mechanism
by which KYNA exerts its regulatory effects on DA cell ﬁring,
including analysis of the role of g-aminobutyric acid (GABA)(A)-,
GABA(B)-, NMDA- and a7* nicotinic receptors in this regard.
2. Materials and methods
2.1. Animals
Experiments were performed on male SpragueeDawley rats
(B&K Universal AB, Sollentuna, Sweden; weighing between 200
and 420 g). The animals were housed in groups of ﬁve, and free
access to food and water was provided. Environmental conditions
were checked daily and maintained under constant temperature
(25 C) and 40%e60% humidity in a room with a regulated 12 h
light/dark cycle (lights on at 06.00). Experiments were approved by
and performed in accordance with the guidelines of the Ethical
Committee of Northern Stockholm, Sweden, and all efforts were
made to minimize the number of animals used and to optimize
their well-being.
2.2. Single unit recording
Rats were anesthetized (chloral hydrate, 400 mg/kg, i.p. or, in a
few pilot experiments, pentobarbital, 60 mg/kg, i.p.) and mounted
onto the ear bars of a conventional stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA) so that the skull was set in a hori-
zontal plane and the nose was secured using a clamp at the front of
the frame. For i.v. administration, a cannula was inserted into a
lateral tail vein and additional injections of chloral hydrate were
given as needed to maintain a stable level of anesthesia. Drugs werealso given through the lateral tail vein cannula. Throughout the
experiments, the body temperature of the animals was maintained
at 37 C by means of a thermostatic heating pad. The skull surface
was exposed and a 3 mm burr hole was drilled with its center
located approximately 3.0 mm anterior to the lambda and 0.7 mm
lateral to the midline. Following careful removal of the dura, a glass
microelectrode with a tip diameter of approximately 1e2 mm (ﬁlled
with 0.5 M sodium acetate saturated with Pontamine Sky Blue) was
lowered by means of a hydraulic micro drive (David Kopf In-
struments, Tujunga, CA, USA) into the region of VTA, according to the
stereotaxic coordinates from the atlas of Paxinos andWatson (1998).
The in vitro impedance of the electrode was between 6 and
8MU, measured at 135Hz in 0.9% saline. Single unit potentials were
passed through a high input-impedance ampliﬁer and ﬁlters. The
impulses were discriminated from background noise and fed into a
computer, and simultaneously displayed on a digital storage oscil-
loscope, monitored on an audio monitor and on a strip chart
recorder (Gould). All DA neurons were found 7.5e8.5 mm from the
brain surface and fulﬁlled the neurophysiological characteristics
(i.e. triphasic action potentials with a duration more than 2.0 ms,
basal ﬁring rates between 1 and 10 Hz and frequent occurrence of
burst ﬁring including progressively decreasing spike amplitude)
previously described for DA neurons in the VTA (Grace and Bunney,
1984a, b). To further conﬁrm that recordings had been made
exclusively from DA neurons, the inhibitory action of a single dose
of the DA agonist apomorphine (100 mg/kg, i.v.) was veriﬁed at the
end of the experiments when the experiments allowed.
In order to determine the number of spontaneously active DA
neurons a microelectrode was lowered 2.8 mm anterior to the
lambda and 0.7 mm lateral to the midline. The electrode was sub-
sequently moved in a predetermined grid pattern with each grid
separated by 200 mm, 2.8e3.6 mm anterior to the lambda and
0.7e0.9 mm lateral to the midline. The mean number of DA cells
found in each track as well as their ﬁring characteristics was
assessed between 4 and 6 h after administration of PF-04859989 or
vehicle. All recorded VTA DA neurons were found 7.5e8.5 mm from
the brain surface and fulﬁlled the neurophysiological characteris-
tics as described above.
2.3. Data analysis
The distribution of spikes was analyzed on line utilizing a Spike
II software program. In order to avoid artifacts in the sampling
procedure, the program was set to ignore time intervals below
20 ms. The onset of a burst was determined as an inter-spike in-
terval shorter than 80 ms and the termination of a burst by the next
interval longer than 160 ms (Grace and Bunney, 1984a, b). Cells
were considered to be bursting if at least one interspike time in-
terval of 100 recorded spikes was below 80 ms. The intervals were
analyzed with regard to the number of bursts that occurred during
a sampling period of 100e500 spikes alongwith a calculation of the
percentage of spikes ﬁred in bursts.
2.4. Analysis of kynurenic acid
Brains were homogenized in 0.4 M perchloric acid (containing
0.1% sodium metabisulﬁte, 0.05% EDTA) using a disperser (Ultra-
Turrax®, IKA, Stauffen, Germany). For analysis of KYNA, an isocratic
reversed-phase high-performance liquid chromatography (HPLC)
system was used, including a dual piston, high pressure liquid de-
livery pump (Bischoff, Leonberg, Germany), a ReproSil-Pur C18
column (4  150 mm, Dr. Maisch GmbH, Ammerbuch, Germany)
and a ﬂuorescence detector (Jasco Ltd, Hachioji City, Japan) with an
excitation and emission wavelength of 344 nm and 398, respec-
tively). Amobile phase of sodium acetate (50mM, pH 6.20, adjusted
Fig. 1. Effect of the KAT II-inhibitor PF-04859989 (5 or 10 mg/kg, i.v.) on a) ﬁring rate and b) burst activity of VTA DA neurons in controls (n ¼ 9e15) and in rats pretreated with MLA
(4 mg/kg, i.p., 15e32 min, n ¼ 5e10), CGP-52432 (10 mg/kg, i.p., 21e33 min, n ¼ 5e7), picrotoxin (4.5 mg/kg, i.p., 20e55 min, n ¼ 5e8) or D-cycloserine (30 mg/kg, i.p., 21e50 min,
n ¼ 4e6). In a) comparisons were made versus corresponding value from PF-04859989 treated control rats (5 mg/kg; *P < 0.05, **P < 0.01, ***P < 0.001, ManneWhitney U test). In b)
changes in burst ﬁring activity for each treatment group were compared to basal value and control value prior to the administration of PF-04859989 (5 mg/kg; *P < 0.05, **P < 0.01,
***P < 0.001 vs. corresponding value before administration of PF-04859989, Wilcoxon matched-pairs sign ranked test. #P < 0.05 vs. controls, ManneWhitney U test). Each value
represents mean ± SEM.
K.R. Linderholm et al. / Neuropharmacology 102 (2016) 42e4744with acetic acid) and 7% acetonitrile was pumped through the
reversed-phase column at a ﬂow rate of 0.5 ml/min 30 ml samples
were manually injected (Rheodyne, Cotati, CA, USA). Zinc acetate
(0.5 M, not pH adjusted) was delivered post column by a syringe
pump (P-500, Pharmacia, Uppsala, Sweden) at a ﬂow rate of 10 ml/
h. The signals from the ﬂuorescence detector were transferred to a
computer for analysis utilizing Datalys Azur (Grenoble, France). The
retention time of KYNA was about 7 min.
2.5. Statistics
All data are expressed as mean ± SEM. Statistically signiﬁcant
differences were established using two-way ANOVA followed by
ManneWhitney U-Test. Differences in per cent spikes ﬁred in
bursts were established using two-way ANOVA followed by Man-
neWhitney U-Test or Wilcoxon signed rank test. Signiﬁcance was
assumed for all values where p < 0.05.
2.6. Drugs and chemicals
The following drugs were used: chloral hydrate (Merck, Darm-
stadt, Germany), PF-04859989 (Kindly donated by Pﬁzer, USA),CGP-52432 (kindly donated by Dr Olpe, Novartis Pharma Inc.),
methyllycaconitine (MLA, Tocris, Avonmouth, UK), isoﬂurane
(Forene®, Abbott Scandinavia, Solna, Sweden), KYNA, Picrotoxin
and D-cycloserine (Sigma, St. Louis, MO, USA). The chemicals used
were: zinc acetate (Sigma, St. Louis, MO, USA), sodium acetate
(Riedel-de Haen, Germany), perchloric acid (Kebo Lab, Stockholm,
Sweden) and acetonitrile (Labasco, Partille, Sweden).
3. Results
3.1. VTA DA ﬁring following acute administration of PF-04859989
The electrophysiological characteristics of VTA DA neurons were
monitored for 45 min. Administration of PF-04859989, a selective
KAT II-inhibitor, (5 mg/kg, i.v., n ¼ 9e15) was associated with a
time-dependent decrease in ﬁring activity observed within 5 min
and a decrease in per cent burst ﬁring observed within 15 min
(Fig. 1a and b). Both ﬁring rate and burst ﬁring activity was reduced
to about 50 per cent 45min after administration. The higher dose of
PF-04859989 (10mg/kg, i.v., n¼ 5e11) did not signiﬁcantly differ in
effect on ﬁring rate or burst ﬁring activity from the lower dose. In a
few experiments, pentobarbital was used for anesthesia instead of
Fig. 2. Whole brain KYNA levels after administration of PF-04859989, (5 mg/kg) at
45 min, (i.v.) or 5 h (i.p). Bars represent mean ± SEM, **P < 0.01 vs. controls, Man-
neWhitney U test.
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shown) showed practically identical electrophysiological responses
to PF-04859989 as compared to those recorded in rats anesthetized
with chloral hydrate, indicating that the inhibitory action of the
KAT II inhibitor is not restricted to chloral hydrate anesthesia.
Pretreatment with D-cycloserine, a partial agonist at the glycine
site of the NMDA-receptor, (30 mg/kg, i.p., n ¼ 4e5, 21e50 min)
prevented the inhibitory action of PF-04859989 (5 mg/kg, i.v.) on
ﬁring rate (Fig. 1a) and burst ﬁring activity (Fig. 1b, ManneWhitney
U-test). Similarly, pretreatment with CGP-52432, a selective in-
hibitor of the GABA(B) receptor, (10 mg/kg, i.p., n ¼ 5e7,
21e33 min) inhibited the action of PF-04859989 (5 mg/kg, i.v.,
Fig. 1). Pretreatment with picrotoxin, a noncompetitive antagonist
of the GABA(A) receptor, (4.5 mg/kg, i.p., n ¼ 5e8, 20e55 min) was
found to partially prevent the inhibitory effect on ﬁring rate and
burst ﬁring activity of PF-04859989 (5mg/kg, i.v.), whereasMLA, an
antagonist of a7* nicotinic receptors, (4 mg/kg, i.p., n ¼ 5e10,
15e32 min) was without effect in this regard (Fig. 1).
Pretreatment with D-cycloserine, MLA, CGP-52432 or picrotoxin
did not signiﬁcantly alter basal cell ﬁring rates (6.2 ± 0.9 Hz;
6.8 ± 0.8 Hz; 5.6 ± 0.7 Hz; 5.7 ± 1.0 Hz, respectively) compared to
controls (6.1 ± 0.5 Hz). Animals pretreated with CGP-52432 or
picrotoxin showed signiﬁcantly lower per cent burst activity
compared to controls but this difference was absent already 5 min
after administration of PF-04859989 (Fig. 1b).3.2. Brain KYNA concentration following administration of PF-
04859989
Intravenous administration of PF-04859989 (5 mg/kg, 45 min)Fig. 3. Effect of pretreatment with PF-04859989 (5 mg/kg, i.p, 4e6 h) on VTA DA cell activ
track, b) ﬁring rate and c) burst activity. Bars represent mean ± SEM, **P < 0.01 vs. controlin a chloral hydrate anesthetized rat (n ¼ 6) did not change whole
brain KYNA concentrations compared to saline controls (Fig. 2). In
contrast, analysis 5 h after the administration of PF-04859989
(5 mg/kg, i.p) revealed a marked reduction in whole brain KYNA
levels (mean value: 2.70 nM ± 0.31, n ¼ 6), compared to saline
treated control rats (10.7 nM ± 1.3, n ¼ 6; p < 0.01).
3.3. VTA DA ﬁring following 5 h pretreatment with PF-04859989
Rats receiving saline (i.p., 5 h, n ¼ 5 rats, 41 cells) showed an
average of 2.4 ± 0.32 spontaneously active DA neurons per elec-
trode track, with a mean ﬁring rate of 3.6 ± 0.26 Hz and 20.2 ± 3.2%
of action potentials ﬁred in bursts (Fig. 3). Rats receiving PF-
04859989 (5 mg/kg, i.p., 5 h, n ¼ 5 rats, 16 cells) exhibited a
signiﬁcantly lower number of spontaneously active DA neurons per
track (0.69 ± 0.08, p < 0.01) compared to controls, although the
remaining active DA neurons showed no difference in average
ﬁring rate (4.2 ± 0.69 Hz) and action potentials ﬁred in bursts
(31.0 ± 8.2%) compared to controls (Fig. 3).
4. Discussion
Inhibition of KAT II may serve as a potentially valuable phar-
macological strategy in the treatment of diseases that are associ-
ated with an excess of KYNA, including psychiatric disorders like
schizophrenia and bipolar disorder. PF-04859989 is a KAT II in-
hibitor that has been extensively studied with regard to potency
and selectivity (Kozak et al., 2014). The results of the present study
show that administration of this compound, in doses that produce a
reduction in extracellular ﬂuid of KYNA (Kozak et al., 2014)
decreased ﬁring rate and burst ﬁring activity of VTA DA neurons in
rats anesthetized with chloral hydrate. Our electrophysiological
ﬁndings are in line with previous studies from our laboratory
showing that a decrease in brain KYNA by the selective cyclo-
oxygenase (COX)-2 inhibitor parecoxib, results in a decreased ﬁring
rate and burst ﬁring activity of midbrain DA neurons (Schwieler
et al., 2006, 2008). Correspondingly, these neurons show
increased ﬁring rate and burst ﬁring activity in rats with pharma-
cologically elevated brain levels of KYNA (Erhardt et al., 2001;
Erhardt and Engberg, 2002; Nilsson et al., 2006; Schwieler et al.,
2006; Linderholm et al., 2007; Olsson et al., 2009).
The afferent control of VTA DA neurons emanates from a variety
of different sources (see Grace et al., 2010). The increase in ﬁring
rate and burst ﬁring activity of VTA DA neurons observed following
elevated brain KYNA concentrations are possibly mediated through
disinhibition of GABAergic afferent regulation of the VTA. Major
regulators of the mesolimbic DA system are local interneurons (Tan
et al., 2012; van Zessen et al., 2012) and themedial prefrontal cortex
(Christie et al., 1985; Carr and Sesack, 2000; Sesack and Carr, 2002)
that directly, or indirectly via the basolateral amygdala, project to
VTA DA neurons (Patton et al., 2013). Notably, our present resultsity compared to vehicle. a) Numbers of spontaneously active cells found per electrode
s, ManneWhitney U test.
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reduction in spontaneously active DA cells concomitant with an
apparently unaffected ﬁring rate and burst ﬁring activity of the
remaining cells. This phenomenon is in line with a recent study
utilizing pharmacological stimulation of the infralimbic medial PFC
(Patton et al., 2013). In analogy with this, the presently observed
suppression in neuronal DA activity in the VTA by a KAT II inhibitor
would reﬂect an activation of GABAergic afferents as a result of an
increased glutamatergic tone induced by a lowering of endogenous
level of KYNA. Indeed, pretreatment with GABA receptor antago-
nists attenuated or blocked the decrease in ﬁring rate seen after
reduced levels of KYNA. This inhibition was most prominent using
the CGP52432, a GABA(B)-receptor antagonist, whereas the
GABA(A)-receptor antagonist picrotoxin was less effective.
Although it was recently shown that GABA(A) receptors preferably
regulates ﬁring of VTA DA neurons by local GABAergic interneurons
(Tan et al., 2012), present results principally indicate a more
prominent role of the GABA(B)-receptor in this regard. Our ﬁndings
are in line with previous observations demonstrating that GABA(B)
receptors in the VTA are predominantly localized on DA neurons (Xi
and Stein,1999) and directly inhibit VTA DA neurons (Engberg et al.,
1993; Margolis et al., 2012).
Although previous studies have shown that local administration
of KYNA in the rat striatum decreases terminal DA release via a
speciﬁc blockade of the a7* nicotinic receptor (Rassoulpour et al.,
2005) the interaction between KYNA and a7 nACh receptors is
still a matter of controversy (for review see Albuquerque and
Schwarcz, 2013). Furthermore, our previous studies have repeat-
edly shown that increase in ﬁring of midbrain DA neurons is spe-
ciﬁcally mediated by blockade of the glycine-site of the NMDA
receptors (Erhardt and Engberg, 2002; Schwieler et al., 2004;
Linderholm et al., 2007). The present study provides further sup-
port for this hypothesis: the decrease in VTA DA neuron ﬁring rate
following reduced brain levels of KYNA was prevented by pre-
treatment with D-cycloserine, a glycine-site agonist of NMDA re-
ceptors. In contrast, pretreatment with MLA, an antagonist of the
a7* nicotinic receptor failed to block the effects of the KAT-II in-
hibitor on DA ﬁring activity. Although only one dose of MLA was
administered (4 mg/kg) our results support the notion that
blockade of the glycine site of the NMDA receptor, rather than
antagonism of the a7* nicotinic receptor, is the mechanism by
which KYNA modulates ﬁring rate on midbrain DA neurons.
Furthermore, these results are in line with previous studies where
systemic administration of NMDA receptor antagonists, such as
PCP, MK-801, and L-701,324, are associated with increased ﬁring
rate and percent burst ﬁring in midbrain DA neurons (French et al.,
1991, 1993; Zhang et al., 1992; Schwieler et al., 2006).
In the present study, administration of PF-04859989 was asso-
ciated with a marked lowering (75%) in whole brain KYNA (5 mg/
kg, i.p. n ¼ 5) 5 h after administration. This is comparable to a
previous microdialysis study in freely moving rats showing that
systemic administration of PF-04859989 is associated with a dose-
related reduction in striatal or cortical extracellular KYNA to a
similar extent (Kozak et al., 2014). However, in contrast to the
relatively instantaneous effects of PF-04859989 on VTA DA ﬁring
and on brain KYNA observed by Kozak et al., present results show
no effect of the drug onwhole brain KYNAwithin the time course of
the electrophysiological experiment (45 min). A conceivable
explanation for this discrepancy may be that whole brain analysis
would also include a considerable intracellular pool of KYNA not
detectable by microdialysis. Although the mechanisms of KYNA
storage and release are not fully understood, the existence of two
distinct intracellular KYNA pools has been suggested, which are
preferentially responsible for KYNA storage and its rapid mobili-
zation (Wu et al., 1992; Schwarcz et al., 2012). Therefore,measurement of total brain concentration of KYNA may not faith-
fully indicate its concentration at the sites of the receptors that
mediate the pharmacological effects reported here.
5. Conclusions
In this study, the novel bloodebrain barrier penetrating KAT-II
inhibitor PF-04859989, which effectively reduces brain levels of
KYNA, decreases ﬁring activity of midbrain DA neurons. Thus, our
results support a physiological role of KYNA to control DA ﬁring,
preferentially by modulating the number of spontaneously active
cells. Hereby, a reduction in brain KYNA levels has a potential to
treat hyperdopaminergic conditions that are generally associated
with schizophrenia and bipolar disorder. Given the role of gluta-
mate and acetylcholine signaling in memory processing, the
pharmacological proﬁle of KYNA, including blockade of both
NMDA- and a7* nicotinic receptors, principally indicate that this
endogenous compound may be of pathophysiological relevance
also in cognitive impairments seen in several mental disorders.
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